Matthew L. Stoll
Following the implementation of standardized protocols for intravenous therapy use at a pediatric rheumatology infusion center, only 1.9% of all infusions were associated with adverse events, according to findings published in Pediatric Rheumatology.
“With medications such as rituximab and infliximab, it is estimated that up to 10% of adults have an infusion reaction severe enough to warrant permanent discontinuation of therapy,” Matthew L. Stoll, MD, PhD, MSCS, from Children’s of Alabama and the University of Alabama at Birmingham (UAB) School of Medicine,
Original Article: Less than 2% of infusions for pediatric rheumatic diseases result in adverse events